Big Tech's Asset-Light Era Is Ending: AI Capex Now Outruns the Cash Flow It Once Minted
The four largest hyperscalers are converting a decade of surplus cash into fixed assets faster than AI revenue can justify — forcing investors to underwrite return on capital, not the earnings growth that carried the trade until now.
Read More
How Private Credit Is Displacing Bank Debt in Leveraged Buyouts: What It Means for Deal Valuations
<
Where April 2025 Digital Health Capital Actually Went
April 2025's biggest digital-health cheques went to diagnostics, metabolic hardware, care-operations software, and fertility infrastructure. Where value compounds next.
Read More
The GLP-1 Endgame: Value Is Migrating Off the Molecule
Lilly catches Novo, Ypsomed sells diabetes care, Virta cuts GLP-1 use, WeightWatchers files Chapter 11. Where the next decade of obesity-care value sits.
Read More
Neumarz Market Outlook January 2026
2026 M&A trends: why European and Swiss buyers are targeting US assets, plus outlook on healthcare, financial services, and energy consolidation.
Read More
The 2026 Strategic Horizon: Capital Allocation in an Era of Physical Scarcity and Fiscal Dominance
As the 2023-2025 cycle concludes, market consensus suggests a fundamental regime change. The "high nominal growth" era is giving way to a period defined by shrinking cash yields, physical resource constraints, and aggressive industrial policy.
Read More
March 2025 Financial Outlook: The Moment of Reckoning – Markets, Policy, and the Art of Staying Ahead
Markets are shifting faster than ever. Germany is spending big, America is...
Read More